Davis Todd C
Chief Executive Officer
Davis Todd C has filed 6 SEC Form 4 filings (15 transaction rows) across 2 companies, including LGND, PTHS, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Jul 6, 2026.
On the most recent filing, Davis Todd C is listed as Director at Pelthos Therapeutics Inc. Inside the rolling window, Davis Todd C reported 1 open-market purchase totaling $1000K in PTHS and no open-market sales.
Companies traded
Other insiders at LGND
Insider Buying
$1000K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Davis Todd C made?
Davis Todd C has filed 6 SEC Form 4 filings (15 transaction rows) across 2 companies, including LGND, PTHS since 2025.
Which companies does Davis Todd C trade?
Davis Todd C has filed SEC Form 4 disclosures for 2 companies, including LGND, PTHS.
When was Davis Todd C's most recent SEC Form 4 filing?
Davis Todd C's most recent SEC Form 4 filing on Tracefour is dated Jul 6, 2026.
What is Davis Todd C's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Davis Todd C is listed as Chief Executive Officer.
What is Davis Todd C's total buy and sell value in the current window?
Inside the rolling retention window, Davis Todd C bought $1000K and sold $0 based on SEC Form 4 filings.
What was Davis Todd C's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 35,948 PTHS shares on 2026-06-11, worth $1000K, per SEC Form 4 filings.